



# Press Release

## New report assesses progress on biosimilar medicine policies across Europe

For Immediate Release

Date of release: 30 March 2021

Biosimilar medicines are increasingly relevant to public health as emphasised by the new [Pharmaceutical Strategy for Europe](#). The latest [Biosimilar Market Review](#) provides a comprehensive overview of policies in 26 European countries focusing on availability, pricing systems, retail markets, hospital tendering, reimbursement systems, healthcare practitioner-related policies, information and education.

Since the first approval of a biosimilar medicine in 2006, we have accumulated over 2 billion patient treatment days in Europe alone, transforming treatment by enabling smart reinvestment of healthcare resources in better access to biological treatments while contributing to the sustainability of European healthcare budgets.

While there are still gaps in access across Europe, biosimilar medicine competition has massively increased the number of patients that can be treated. A recent IQVIA report on The Impact of Biosimilar Competition in Europe, highlighted the critical role that biosimilar medicines will play in the future as many more biological medicines are set to lose market (IP) exclusivity. This should compel the EU and member states to implement efficient, goal-oriented biosimilar medicine policies to improve patient access and healthcare sustainability. This should be based on highly successful benefit-sharing models that have proven the ability to stimulate competition and uptake.

Commenting on the launch of the Biosimilar Market Review Kelly Burke, chair of the biosimilar market access committee of Medicines for Europe said: *“The Biosimilar Market Review is an important resource for stakeholders and policy-makers interested in improving access to biological therapies. While progress has been made, it is clear much more can be done to leverage benefit-sharing for better access for patients and for a more sustainable healthcare.”*

The 2020 Biosimilar market review can be accessed [here](#).

### The Biosimilar Medicines Group

The Biosimilar Medicines Group is a sector group of **Medicines for Europe** representing the leading companies developing, manufacturing and/or marketing biosimilar medicines across Europe. With more than 10 years of positive patient treatment experience and 20 products successfully launched, biosimilar medicines provide today a huge opportunity to deliver significantly improved access to modern therapies for millions of European patients in both chronic and acute care. Our members bring competition to the biological medicines market, thereby

increasing access to highly innovative treatments to patients, in Europe and around the world, and supporting the sustainability of the European healthcare systems.

## About Medicines for Europe

---

**Medicines for Europe** represents the generic, biosimilar and value added medicines industries across Europe. Its vision is to provide sustainable access to high quality medicines, based on 5 important pillars: patients, quality, value, sustainability and partnership. Its members directly employ 190,000 people at over 400 manufacturing and 126 R&D sites in Europe, and invest up to 17% of their turnover in R&D investment. Medicines for Europe member companies across Europe are both increasing access to medicines and driving improved health outcomes. They play a key role in creating sustainable European healthcare systems by continuing to provide high quality, effective generic medicines, whilst also innovating to create new biosimilar medicines and bringing to market value added medicines, which deliver better health outcomes, greater efficiency and/or improved safety in the hospital setting for patients. For more information please follow us at [www.medicinesforeurope.com](http://www.medicinesforeurope.com) and on Twitter [@medicinesforEU](https://twitter.com/medicinesforEU).